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Objective: To evaluate whether prophylactic administration of surfactant is superior to early
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(RDS).
Methods: We prospectively compared small premature infants (< 32 weeks) receiving 70 mg/
kg bovine surfactant within 30 minutes after birth (prophylactic group, N Z 116) with infantsNeonatology, Director of Bayi Children’s Hospital, Military General Hospital of Beijing P.L.A., No. 5
rict, Beijing 100700, China.
m (Z. Feng).
. They are joint first authors.
015.03.007
Pediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the
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20 X. Kong et alwho received surfactant therapy for established RDS (early treatment group, NZ 91). The pri-
mary outcome assessed was the incidence of RDS. The secondary outcomes assessed were
severity of RDS, mortality, and bronchopulmonary dysplasia morbidity.
Results: Compared with the early treatment group, the prophylactic group had a significantly
better PaO2 (at 1 hour, 4 hours, and 12 hours postdose, respectively), better a/APO2 (at 1 hour,
4 hours, 12 hours, and 24 hours postdose, respectively), lower PaCO2 (at 1 hour postdose), and
a significantly decreased need for mean airway pressure (MAP) and FiO2 on ventilation
(p < 0.05). The prophylactic group had shorter durations for mechanical ventilation and sup-
plemental oxygen compared with the early treatment group (p < 0.01 and p < 0.05, respec-
tively). The incidence of RDS was comparable between the groups; however, the
prophylactic group had a significantly lower incidence of severe RDS and significantly lower
rate of repeated doses of surfactant than the early treatment group (p < 0.05). The incidences
of bronchopulmonary dysplasia and patent ductus arteriosus were also lower in the prophylac-
tic group than the early treatment group (p < 0.05). The two groups were comparable in mor-
tality rate.
Conclusion: In preterm infants under 32 weeks’ gestation, prophylactic use of a domestic sur-
factant preparation is better than early surfactant treatment in improving pulmonary status
and in decreasing the incidence of severe RDS and duration on mechanical ventilation.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
More than 50 years after the discovery that infants with
respiratory distress syndrome (RDS) were deficient in pul-
monary surfactant, and more than two decades after the
introduction of exogenous surfactant for routine clinical
use in neonates, questions remain concerning the optimal
treatment strategy. There are two basic approaches to
therapy. Surfactant may be administered soon after birth as
prophylaxis to infants who are at risk of developing RDS, or
later as rescue treatment for infants who have developed
signs of respiratory distress. Multiple randomized
controlled trials have demonstrated that both of these
therapeutic approaches are safe and effective1,2; however,
controversy remains over how to select infants for pro-
phylactic treatment and how soon after birth to initiate
therapy. The conventional view has been challenged by
recent studies, particularly in those studies including
antenatal steroid and continuous positive airway pressure
(CPAP) in the delivery room.3 Many neonatal units still lack
standardized protocols for surfactant treatment. As a
result, there is likely to be considerable variation in sur-
factant treatment practices both within and among
neonatal intensive care units (NICUs); however, data on
these practices are not currently available.
In China, there are no reports on the efficacy and safety
of the prophylactic use of domestic surfactant Calsurf
(Beijing Double-Crane Pharmaceutical Co., Ltd., Beijing,
China), although it has shown good efficacy for many years.
We designed a national multicenter controlled trial to
compare the administration of prophylactic surfactant with
early selective surfactant treatment in small preterm in-
fants. We included data for infants who were 25e31 weeks’
gestation, born from 2012e2013, and cared for at the nine
NICUs in China. These analyses provided a detailed
description of current surfactant treatment practices andallowed us to evaluate how the available evidence trans-
lated into routine practice.2. Patients and methods2.1. Trial centers
This study was a national, multicenter, open-label,
controlled study approved by independent ethics commit-
tees in accordance with the requirements of each partici-
pating unit in China. The study was conducted as part of the
Neonatal Research Network of the Chinese Neonatologist
subassociation of the Chinese Medical Doctor Association. It
was conducted in accordance with good clinical practice
guidelines and the study protocol in each unit.2.2. Study design
During the study period, surfactant was given to the
following infants: (1) infants with gestational age (GA) from
25 weeks and 0 days to 27 weeks and 6 days, and (2) infants
with GA from 28 weeks and 0 days to 31 weeks and 6 days
and with at least three of the following factors: (1) mothers
with diabetes or gestational diabetes; (2) male infants; (3)
multiple births; (4) mothers without antenatal steroid or
who received insufficient dose; (5) emergency intubation
requirement after birth; and (6) severe respiratory distress
shortly after birth highly suggestive of RDS. Exclusion
criteria were severe birth asphyxia or a 5-minute Apgar
score  3; known genetic disorders; potentially life-
threatening conditions unrelated to prematurity; and pre-
mature rupture of membranes of  3 weeks. Written
informed consent was obtained before delivery.
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All of the infants in the prophylactic group were intubated
in the delivery room and received surfactant within 30
minutes after birth, and preferably within 15 minutes. In
the early treatment group, surfactant was administered in
a timely manner from 30 minutes to 2 hours after birth
when infants suffered from apnea, required supplemental
oxygen, exhibited significant respiratory distress, required
positive airway pressure ventilation, or showed a charac-
teristic chest radiographic appearance (uniform retic-
ulogranular pattern and peripheral air bronchograms).4
Neither randomization nor a double-blind design was
employed in this study. Both groups were observed from
birth to NICU discharge or clinical death.
2.4. Surfactant preparation and doses
The surfactant used in this study was a newborn bovine lung
surfactant extract (Calsurf) with surfactant lyophilized
powder in a 70 mg/vial, refrigerated at 10C prior to use.
Two milliliters of sterile water were injected into the vial
containing the surfactant powder and the vial was then
shaken to form a suspension. After raising the temperature
of the suspension to approximately 37C, the suspension
was administered through the endotracheal tube at a dose
of 70 mg/kg. Endotracheal suction was avoided within 6
hours when possible. Infants receiving surfactant were
eligible to receive up to three additional doses within the
first 2 days of life. Repeated doses were indicated under
the following conditions: (1) no significant improvement in
respiratory symptoms observed after the first dose and
chest X-ray indicated no remission or worsened RDS; (2)
mechanical ventilation was required and a PaO2 > 50 mmHg
could only be maintained with FiO2  0.40 and mean airway
pressure (MAP)  9 cm H2O; and (3) arterial/alveolar oxy-
gen ratio (a/APO2) < 0.22, Where “a” is the PaO2 from
blood gas determination and APO2 Z PaO2  713 e
(PaCO2)/0.8. Repeat doses were administered at a dose of
70e100 mg/kg at an interval of 8e12 hours.
2.5. Respiratory management
All infants followed a protocol for respiratory care. Infants
were not supported with nasal CPAP (nCPAP) within 2 hours
after birth and intubated only if they needed to be given
surfactant. All infants in both groups received at least 1e3
hours of ventilation after surfactant administration. The
infants were extubated on CPAP after meeting all of the
following criteria: PaCO2 < 50 mmHg and pH > 7.30; FiO2 
0.35 with SpO2  88%; MAP  7 cm H2O; ventilator rate of 
20 breaths per minute; and hemodynamic stability without
evidence of clinically significant PDA.
Infants who received nCPAP were initially supported
with a pressure of 5 cm H2O, which could be increased to a
maximum of 7 cm H2O. Short, binasal prongs were used as
the interface. CPAP was generated by continuous gas flow
delivered through a heated, humidified circuit. We
attempted to maintain infants on nCPAP for at least 72
hours after extubation and until 1 week of age if they
required supplemental oxygen. After the 1st week, thedegree and method of respiratory support were determined
by the clinicians caring for the infant. Once the infants
were extubated, they were treated according to the stan-
dard practice in the NICU to which they had been admitted.
The ventilator parameters were adjusted adequately ac-
cording to the clinical condition, blood gas values, and
chest X-ray in both the preventive group and early treat-
ment group if mechanical ventilation was still required
after surfactant administration.
2.6. Outcome evaluation
For the determination of pH, PaO2, PaCO2, and calculating
the a/APO2 ratio as to evaluate the response after the first
dose of surfactant, arterial blood gas analysis was per-
formed at 1 hour, 4 hours, 12 hours, and 24 hours postdose,
respectively. Ventilator settings including MAP and FiO2
were recorded simultaneously with the blood gas analysis.
Total durations of ventilator support and oxygen inhalation
were recorded at the end of the observation period.
The primary outcomes were the incidence of RDS. RDS
was defined according to the clinical features, and radio-
graphic findings.5 Chest radiograph was performed at 12
hours and 24 hours postdose. RDS was classified as one of
four grades depending on severity, with Grades III and IV
defined as severe RDS. The diagnosis of RDS was made
independently by two neonatologists, blinded to the
treatment groups. The major complications were compared
between the two groups using the following diagnostic
criteria5e7: (1) moderate to severe bronchopulmonary
dysplasia (BPD) defined as patients who required mechan-
ical ventilation or oxygen inhalation 28 days after birth and
still required oxygen inhalation at 36 weeks corrected GA;
(2) severe intraventricular hemorrhage (IVH) defined as
Grades III and IV according to the Papile grading system
based on head ultrasound performed during hospitalization;
(3) high grade necrotizing enterocolitis (NEC) defined on
the basis of clinical signs combined with radiographic evi-
dence of intra-abdominal ectopic gas, or the need for any
bowel surgery (high grade NEC was  Grade II according to
modified Bell’s criteria); (4) sepsis, including positive blood
culture and clinical diagnosis; (5) patent ductus arteriosus
(PDA) confirmed using two-dimensional echocardiography
after admission; (6) air leak syndrome including pneumo-
thorax, pulmonary interstitial emphysema, and mediastinal
emphysema, with the diagnosis confirmed mainly by chest
X-ray findings; and (7) pulmonary hemorrhage defined as a
nontraumatic gush of bloody secretion from the endotra-
cheal tube associated with clinical deterioration requiring
increased ventilator support. Duration of mechanical
ventilation and supplemental oxygen, and total hospital
stay were also calculated.
2.7. Sample size determination and statistical
analysis
Based on our previous experience in China, for these high
risk infants selected for the study, the incidence of RDS was
w50%. We speculated that, with prophylactic surfactant
therapy, the incidence of RDS could be reduced to 25%.
Allowing for chances of type I errors of 5% and type II errors
22 X. Kong et alof 20%, 90 infants in each group would be needed. An
estimated 120 infants in each group would be an adequate
number for the study. Categorical variables were analyzed
using c2 test and continuous variables were analyzed using
unpaired Student t test. Mean  standard deviation (SD) are
given unless otherwise noted. A two-tailed p < 0.05 was
considered statistically significant. When an infant died
within the study period, the values were included until the
moment of death, and no adjustments were made to allow
for the fact that the sick infant was no longer in the group.
3. Results
We enrolled 254 infants and fully informed parental con-
sent was obtained prior to the delivery for 143 patients in
the prophylactic group and 111 patients in the early
treatment group from October 1st 2012 to September 30th
2013. However, 47 infants were excluded from the study
because of a lack of essential data or because the parents
asked to withdraw from observation. Data from the
remaining 207 infants (81.5% of the enrolled 254) were used
in the final analysis (Figure 1).
3.1. Baseline characteristics
There were no significant differences in GA, birth weight,
Apgar score, use of antenatal steroids, or C-section rate
between the two groups (p > 0.05). However, the prophy-
lactic group had a significantly greater proportion of male
infants than the early treatment group (p < 0.05; Table 1).
3.2. Mechanical ventilation parameters and blood
gas analysis
The PaO2 and a/APO2 levels were significantly higher in the
prophylactic group than in the early treatment group at 1
hour, 4 hours, and 12 hours postdose (p < 0.05), and the
difference in the a/APO2 level remained highly significant
between groups at 24 hours postdose (p < 0.05). The pro-
phylactic group had a significantly lower PaCO2 at 1 hour
postdose compared with the early treatment groupA total of 254 infants were 
enrolled in 9 units.
143 infants in the prophylactic 
group
111 infants in the early treatment group
Twenty-seven patients were 
excluded: 11 infants lacked 
essential data or the parents 
asked to withdraw from 
observation.
Twenty infants were excluded: 8 infants 
lacked essential data or the parents 
asked to withdraw from observation.
116 infants were analyzed in the 
prophylactic group, accounting for 
81.1%.
91 infants were analyzed in the early 
treatment group, accounting for 
82.0%.
Figure 1 Case screening in the two groups.(p < 0.05). Furthermore, mechanical ventilation parame-
ters at 1 hour, 4 hours, and 12 hours postdose in the pro-
phylactic group were significantly lower than those in the
early treatment group (p < 0.05). The prophylactic group
had a significantly lower FiO2 at 1 hour and 4 hours post-
dose than the early treatment group (p < 0.05; Table 2).
3.3. Incidence and severity of RDS
The prophylactic group had a slightly higher incidence of
RDS than the early treatment group, but the value did not
reach significance (p > 0.05). However, the incidence of
severe RDS was significantly lower in the prophylactic group
than that in the early treatment group (p < 0.05). The rate
of repeated doses of surfactant in the prophylactic group
was significantly lower than that in the early treatment
group (p < 0.05; Table 3).
3.4. Complications
There were no statistically significant differences in the
incidence of severe IVH, NEC, air leak syndrome, pulmonary
hemorrhage, or sepsis between the two groups (p > 0.05).
The incidences of moderate and severe BPD and PDA were
much lower in the prophylactic group than in the early
treatment group (p < 0.05; Table 3).
3.5. Outcomes
There were seven deaths in the prophylactic group and eight
deaths in the early treatment group, with survival rates of
94.0% and 91.2%, respectively. There was no statistically
significant difference in survival rate between the two
groups (p > 0.05). Infants in the prophylactic group had
significantly shorter durations of mechanical ventilation and
supplemental oxygen (p < 0.01 and p < 0.05, respectively)
and a slightly shorter duration of hospital stay compared
with the early treatment group (p > 0.05; Table 4).
4. Discussion
A prophylactic, or preventive, surfactant strategy is defined
as intubation and surfactant administration to infants at
high risk of developing RDS for the primary purpose of
preventing worsening RDS rather than treatment of estab-
lished RDS. In clinical studies this involves surfactant
administration in the delivery room before initial resusci-
tation efforts or the onset of respiratory distress or, most
commonly, after initial resuscitation but within 10e30 mi-
nutes after birth. This is in contrast with a rescue or
treatment surfactant strategy, in which surfactant is given
only to preterm infants with established RDS. Surfactant
treatment is most often administered within the first 12
hours after birth when specified threshold criteria of
severity of RDS are met. Recent randomized controlled
trials demonstrated that prophylactic or early surfactant
results in improved outcomes for high-risk preterm infants
compared with delayed rescue surfactant treatment.2,8e10
However, these trials did not provide a definitive answer
to the question of best timing of surfactant application at
Table 1 Demographic and clinical information in the prophylactic and early treatment groups.
Group n Male（%） GA（wks）
<28 28w31
Birth
weight（g）
C-section（%） Antenatal
steroids *（%）
5-min Apgar
score < 8（%）
Prophylactic 116 81（69.8） 9107 1489.8  350.9 53（45.7） 84（72.4） 13（11.2）
Early treatment 91 49（53.8） 1180 1443.9  348.6 44（48.4） 67（73.6） 9（9.9）
t/c2 5.575 1.095 0.3206 0.145 0.846 0.093
p 0.018 0.295 0.7488 0.703 0.970 0.760
GA Z gestational age.
* The number of dexamethasone doses was  2.
Bovine surfactant replacement therapy 23different GAs. In a large North American cohort of 47,608
infants, < 30 weeks gestation born between 1998 and 2000,
only 27% received surfactant in the delivery room and 44%
received surfactant by 30 minutes of age.11 Recent studies,
more often with antenatal steroid therapy and the use of
CPAP in the delivery room, indicated that nCPAP can be
equally as effective as surfactant therapy to improve pul-
monary status and that it can avoid endotracheal intuba-
tion.3 In our study, we asked whether prophylactic
surfactant improved respiratory outcome in very premature
infants under 28 weeks’ gestation and infants under 32
weeks’ with risk factors for RDS.
The 2010 European consensus guidelines recommended
that prophylactic surfactant be administered within 15
minutes after birth in extremely premature infants born
before 26 weeks’ GA and that natural surfactant be
administered to neonates with existing RDS or to those who
are at high risk for RDS.12 However, the 2013 European
consensus guidelines for RDS stressed only the importance
of early use of surfactant, but they did not specify theTable 2 Mechanical ventilation parameters and arterial blood
Group n Blood gas p
pH PaO2
At 1h postdose
Prophylactic 116 7.36  0.13 82.43  66.41
Early treatment 91 7.34  0.10 62.16  57.74
t 1.8190 2.3067
p 0.0704 0.0221
At 4 h postdose
Prophylactic 108 7.34  0.09 73.02  33.38
Early treatment group 84 7.36  0.09 62.13  35.12
t 1.5275 2.1919
p 0.1283 0.0296
At 12 h postdose
Prophylactic 112 7.41  0.09 63.02  39.35
Early treatment 80 7.40  0.09 51.12  39.88
t 0.7590 2.0543
p 0.4488 0.0413
At 24 h postdose
Prophylactic 110 7.36  0.09 65.22  32.34
Early treatment 90 7.37  0.08 56.54  41.89
t 0.8214 1.6532
p 0.4124 0.0999
MAP Z mean arterial pressure.timing of administration. It is recommended that exogenous
surfactant be administered in preterm infants born before
26 weeks’ GA in the case of a FiO2 level of > 0.3 and in
preterm infants born after 26 weeks’ GA with a FiO2 level of
> 0.4.10 The guidelines also indicated that the specific
strategy should vary by unit in the timing of PS use based on
the RDS stage, GA, and antenatal steroid use. According to
the data from Euro NeoStat, the incidence of neonatal RDS
at 23e25 weeks’, 26e27 weeks’, 28e29 weeks’, and 30e31
weeks’ GA was 91%, 88%, 74%, and 52%, respectively.10
Therefore, the incidence of RDS is up to 50% in preterm
infants born before 32 weeks’ GA, which is one of the main
causes of premature death and severe neurological devel-
opment disability. In China, the reported that the incidence
of RDS is approximately 40e50% in preterm infants born
before 32 weeks’ GA.13,14 Therefore, we enrolled all infants
with a GA < 28 weeks or infants with least three of the risk
factors described earlier with GA  28 weeks and < 32
weeks. The baseline characteristics of the newborns in the
two groups were similar for GA, birth weight, 5-minutegas analysis.
arameters Mechanical ventilation
parameters
PaCO2 a/APO2 MAP FiO2
28.96  17.90 0.33  0.19 9.19  1.72 0.36  0.09
34.79  17.48 0.24  0.13 10.03  2.01 0.39  0.12
2.3499 3.8636 3.2373 2.0552
0.0197 0.0001 0.0014 0.0411
40.31  12.49 0.36  0.17 9.14  2.19 0.35  0.10
37.16  14.81 0.25  0.11 10.17  2.46 0.39  0.12
1.5977 5.1494 3.1184 2.5182
0.1118 0.0000 0.0021 0.0126
36.82  15.73 0.36  0.18 8.17  2.93 0.28  0.14
40.58  16.10 0.27  0.12 9.01  2.78 0.30  0.13
1.6170 3.8950 2.0004 1.0051
0.1075 0.0001 0.0469 0.3161
31.66  18.43 0.38  0.19 7.93  2.75 0.28  0.17
27.62  16.81 0.30  0.16 8.12  2.67 0.27  0.11
1.6040 3.1773 0.4925 0.4815
0.1103 0.0017 0.6229 0.6307
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24 X. Kong et alApgar score, the number of doses of antenatal steroids, and
the type of delivery. However, the proportion of male in-
fants was significantly higher in the prophylactic group,
which may have reflected parental preference for prophy-
lactic surfactant because they knew that male infants
predominate in the incidence of RDS. Our staff may have
emphasized that male infants were at high risk for RDS
during conversations with the parents, although the sex of
the infants remained unknown before birth.
Early extensive studies on premature animals with RDS
demonstrated that respiratory outcome was improved and
early lung injury prevented when surfactant was given
prophylactically immediately after birth, rather than on a
selective use basis.15 Serum proteins can leak into alveolar
interstitium at first breath in animals with surfactant defi-
ciency. Exudative proteinaceous material and epithelial
debris, resulting from progressive cellular damage, directly
decrease total lung capacity.15 Theoretically, the earlier
that surfactant is administered, the better the outcome;
however, this is difficult to implement clinically. Some
studies have revealed that the efficacy of surfactant
administered at first breath after birth was not superior to
that of surfactant administered 30 minutes after birth.
However, the prophylactic approach may disrupt the tran-
sitional phase after birth and lead to selective intubation
and expensive treatment of surfactant-sufficient new-
borns.16,17 Some studies have also shown that better out-
comes were achieved when surfactant was administered
within 1e2 hours after birth.4 In China, challenges remain
in the use of surfactant within 15 minutes after birth in the
delivery or operating room even in large-scale hospitals.
Also, there are no obstetrics departments in most children’s
hospitals in China. Therefore, in this study, the timing of
the prophylactic use of surfactant was defined as 30 mi-
nutes after birth, which maximized both the preventive
benefits against neonatal RDS and the clinical feasibility.
As in previous reports, both prophylactic and early
administration of surfactant resulted in fewer incidences of
pneumothorax, less pulmonary interstitial emphysema, and
improved survival without BPD. However, the reported
survival rates differed among the reports, because survival
is affected by many factors, such as GA, birth weight, and
maternal complications during pregnancy.6,7 In this study,
the survival rate was 94.0% for the prophylactic group and
91.2% for the early treatment group, neither of which was
statistically significant, but these were higher than in pre-
vious reports. This finding may be associated with the
relatively large GA and birth weight of the infants enrolled
in this study.18e20 According to the 2010 report by the
American NICHD Neonatal Coordination Group, of 9575
preterm infants born before 29 weeks’ GA, preterm infants
born at 22 weeks’ GA and 28 weeks’ GA had a survival rate
of 6% and 92%, respectively, with an overall survival rate of
72%.20 The Chinese multicenter clinical study of porcine
lung surfactant (Curosurf) trial performed in newborn in-
fants in 2000 revealed that the 10-day and 28-day mortality
rates were 13% and 23%, respectively.21 The multicenter
clinical study of the use of bovine surfactant (Calsurf) for
RDS performed in 2009 revealed that the Calsurf group had
a mortality rate of 8.77%.22 In this study, the infants had
lower GA and birth weight compared with previous trials
reported in China. The prophylactic group had a slightly
Table 4 Comparison of survival rate and durations of mechanical ventilation, oxygen inhalation, and hospital stay.
Group n Survival rate
(%)
Duration of ventilation
(h)
Duration of supplemental oxygen
(d)
Duration of hospital stay
(d)
Prophylactic 116 109 (94.0) 97.9  77.5 13.1  12.8 31.1  18.3
Early
treatment
91 83 (91.2) 137.5  124.9 17.8  16.3 34.5  22.9
c2/t 0.5766 2.7975 2.3241 1.1874
p 0.4477 0.0056 0.0211 0.2364
Bovine surfactant replacement therapy 25higher survival rate compared with that reported in 2009
while the early treatment group had a similar survival rate
to that reported in 2009. The decrease in mortality and
increase in survival rate were closely associated with early
and widespread use of surfactant and improvements in
premature infant management and respiratory support
technologies.13,20
Our study showed that the prophylactic administration
of surfactant could be preferable to rescue treatment, as it
decreased the incidence of severe RDS, BPD, and PDA, but
it could result in some babies being intubated and receiving
therapy unnecessarily, especially babies who had received
a course of antenatal steroids. Controversies remain with
respect to the signs justifying the prophylactic use of sur-
factant.1,2 In a multicenter randomized controlled clinical
study performed by the Vermont Oxford Neonatal Network,
preterm infants of 26e29 weeks’ GA were assigned to one
of three groups. One group received prophylactic surfac-
tant within 15 minutes after birth, followed by mechanical
ventilation. A second group received prophylactic surfac-
tant within 15 minutes after birth, followed by extubation
and nCPAP therapy. A third group received nCPAP therapy
within 15 minutes after birth. The results revealed no sig-
nificant difference in mortality or the incidence of com-
plications between the prophylactic surfactant group and
the nCPAP group (RR Z 0.83, 95% CI: 0.64e1.09). In the
nCPAP group, 48% were managed without intubation and
ventilation, and 46% required surfactant treatment, which
was significantly less than in the other two groups.23 Ac-
cording to data from the SUPPORT Study Group of the
Eunice Kennedy Shriver NICHD Neonatal Research Network,
infants who received CPAP treatment, as compared with
infants who received surfactant treatment soon after birth,
less frequently required intubation or postnatal cortico-
steroids for BPD (p < 0.001), required fewer days of me-
chanical ventilation (pZ 0.03), and were more likely to be
alive and free from the need for mechanical ventilation by
Day 7 (p Z 0.01).3 Also, the 2013 European consensus
guidelines on the management of RDS indicated that both
prophylactic treatment, in which surfactant is administered
shortly after birth to infants at high risk of developing RDS,
or selective therapy, in which surfactant is administered to
infants only after they have exhibited evidence of signifi-
cant RDS, both proved to be effective. However, the best
timing of use of surfactant in neonates of different GAs is
unknown.1,10 There were no large-scale randomized
controlled clinical trials using early nCPAP soon after birth
in neonates in the delivery or operating room in China. The
skill levels and number of equipped facilities are not suf-
ficiently uniform in NICUs throughout China because ofdifferences in geography, economic development, and
population density; therefore, many neonates suffering RDS
have to be transported to high-level NICUs for treat-
ment.24,25 Our results suggest that prophylactic surfactant
administration before transport in neonates at high risk of
RDS would help stabilize neonates and reduce the possible
risks during transportation.
Although this study is not novel and several large clinical
trials proved that the effect of early use nCPAP was similar
to early prophylaxis of surfactant in extremely low birth
weight infants, our results are of interest. Calsurf is the
most often used local domestic preparation of surfactant in
China, with a total yearly birth rate of > 20 million new-
borns. This preparation is cheaper, easily available, and
very popular in China. There were certain limitations and
weaknesses in our study. This study was not designed in a
randomized fashion and imbalance between the partici-
pating hospitals may pose some limitation of the study. We
believe a future large-sample randomized trial is
warranted.Conflicts of interest
The authors have no conflicts of interest relevant to this
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